VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
TRDA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
TRDAEntrada Therapeutics, Inc.
$5.03$195M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksTRDABalance Sheet

Entrada Therapeutics, Inc. (TRDA) Balance Sheet

7Y historyFree accessUpdated daily

Total assets have contracted 41.5% to $298.9M with cash of $99.3M against $48.5M of total debt (D/E 0.21), but the implied two-to-three-quarter runway at current burn rates warrants close monitoring.

Income StatementBalance SheetCash FlowRatios

TRDA Balance Sheet

Annual statement

TRDA Balance Sheet

Entrada Therapeutics, Inc. (TRDA) balance sheet — 7-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Total Current Assets202.95M306.25M440.04M369.77M209.88M298.7M39.95M17.44M
Cash & Short-Term Investments193.01M295.7M420M351.97M188.71M291.06M39.05M16.84M
Cash Only112.24M90.39M101.21M67.6M45.16M291.06M39.05M16.84M
Short-Term Investments80.78M205.3M318.79M284.37M143.56M000
Accounts Receivable838K2.58M3.68M5.88M0000
Days Sales Outstanding117.43376.3716.63----
Inventory00000000
Days Inventory Outstanding--------
Other Current Assets07.98M16.36M11.92M21.16M000
Total Non-Current Assets63.93M71.13M86.28M99.42M42.18M7.13M3.58M801K
Property, Plant & Equipment60.51M67.76M82.05M92.68M33.02M6.26M3.04M801K
Fixed Asset Turnover0.06x0.38x2.57x1.39x----
Goodwill00000000
Intangible Assets00000000
Long-Term Investments00000000
Other Non-Current Assets3.42M3.36M4.23M6.74M9.16M872K541K0
Total Assets266.88M377.38M526.32M469.19M252.06M305.83M43.53M18.24M
Asset Turnover0.01x0.07x0.40x0.27x----
Asset Growth %-128.1%-28.3%12.18%86.15%-17.58%602.63%138.66%-
Total Current Liabilities25.86M24.45M39.48M158.8M21.97M6.72M3.36M1.92M
Accounts Payable4.87M2.29M4.26M3.28M5.99M706K1.6M710K
Days Payables Outstanding746.3203.98----1.79K2.49K
Short-Term Debt00000000
Deferred Revenue (Current)867K342K13.65M132.26M0000
Other Current Liabilities09.22M8.43M7.66M5.49M4.56M1.6M937K
Current Ratio7.85x12.53x11.15x2.33x9.55x44.46x11.89x9.08x
Quick Ratio7.85x12.53x11.15x2.33x9.55x44.46x11.89x9.08x
Cash Conversion Cycle-628.87-------
Total Non-Current Liabilities42.69M46.79M58.16M68.04M17.53M396K81.66M31.84M
Long-Term Debt00000000
Capital Lease Obligations179.05M46.79M51.65M60.32M17.53M000
Deferred Tax Liabilities00000000
Other Non-Current Liabilities00000396K81.66M31.84M
Total Liabilities68.56M71.25M97.64M226.83M39.5M7.12M85.02M33.76M
Total Debt47.31M50.93M59.21M68.23M25.94M000
Net Debt-64.92M-39.46M-42M628K-19.22M-291.06M-39.05M-16.84M
Debt / Equity0.24x0.17x0.14x0.28x0.12x---
Debt / EBITDA-0.28x-1.17x-----
Net Debt / EBITDA0.38x--0.83x-----
Interest Coverage-----34.95x---
Total Equity198.32M306.13M428.68M242.36M212.55M298.72M-41.49M-15.52M
Equity Growth %-143.96%-28.59%76.88%14.02%-28.84%819.98%-167.37%-
Book Value per Share4.687.4010.997.336.799.57-1.33-14.81
Total Shareholders' Equity198.32M306.13M428.68M242.36M212.55M298.72M-41.49M-15.52M
Common Stock4K4K4K3K3K3K00
Retained Earnings-395.32M-273.09M-129.34M-194.97M-188.28M-93.67M-42.51M-15.99M
Treasury Stock00000000
Accumulated OCI-56K652K-43K195K-2.06M000
Minority Interest00000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Cash runway critically short

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Balance Sheet Erosion Accelerating Steadily

Entrada's total assets have contracted 41.5% from $510.8M in 2024Q1 to $298.9M in 2026Q2, driven by persistent cash burn and the collapse of deferred revenue from $157.9M to $173K, according to the company's quarterly balance sheets.

The trajectory is unambiguously negative. Total assets have declined in seven of the last nine quarters with no sign of stabilization, while accumulated deficit has widened from -$171.5M to -$355.6M — a $184M deterioration in retained earnings over the period. The fact that this erosion has continued despite operating expenses exceeding revenue by roughly 46:1 suggests the company is consuming capital at a rate that may not be sustainable beyond 2026.

Cash Buffer Thinning Against Heavy Burn

As reported in Entrada's financial statements, cash stood at $99.3M in 2026Q2 against a current ratio of 10.89, but with quarterly operating losses near $42M, the implied runway appears to be approximately two to three quarters absent new financing.

The current ratio of 10.89 superficially signals abundant liquidity, but this is misleading because current liabilities have collapsed to just $6.0M from $241.5M in 2024Q1 — primarily the elimination of deferred revenue. The more relevant metric is cash relative to operating burn: at roughly $40M+ per quarter of operating cash outflow (as evidenced by the $42.8M net loss in 2026Q2), $99.3M provides a buffer that may require management to seek capital markets access sooner rather than later.

Modest Debt Load Being Gradually Repaid

Based on Entrada's disclosed figures, total debt has declined from $66.4M in 2024Q1 to $48.5M in 2026Q2, with a debt-to-equity ratio of 0.21 that appears manageable relative to the $99.3M cash position.

The gradual ~27% reduction in debt over the period suggests either scheduled amortization or voluntary deleveraging, which is a modest positive. However, the D/E ratio of 0.21 overstates the balance sheet's strength because equity itself has deteriorated from $428.7M to $233.4M; on a cash-adjusted basis, net debt of -$50.8M means the company remains technically net cash positive, which preserves some strategic flexibility for refinancing if needed.

Asset Base Shrinking Without Goodwill Risk

Entrada's balance sheet carries zero goodwill across all ten periods, while net PPE has declined from $90.0M to $62.8M, per the company's quarterly filings, indicating a business whose asset base is concentrated in cash and working capital rather than intangibles.

The absence of goodwill is notable for a biotech and eliminates one common impairment risk that peers like ARWR or NTLA might carry. However, the steady $27M decline in PPE — with capex consistently below $1.1M against depreciation exceeding that in most quarters — signals the company is not reinvesting in its physical infrastructure. For a business still spending $35M+ quarterly on R&D, the fact that tangible assets are shrinking suggests the R&D spend may be primarily personnel- and partnership-driven rather than capital-intensive laboratory work.

Deferred Revenue Collapse Obscures True Health

The most underappreciated balance sheet distortion is deferred revenue plunging from $157.9M in 2024Q1 to $173K by 2026Q2, which masked the severity of the cash burn by artificially inflating total liabilities and equity in prior periods.

The $157.9M of deferred revenue in early 2024 represented previously collected cash that had not yet been recognized as revenue. As this obligation was liquidated — either through revenue recognition or refund — it simultaneously reduced total liabilities (improving the current ratio optics) and reduced equity through the associated revenue/expense recognition. This means the balance sheet's apparent improvement in leverage and liquidity ratios over the period is substantially a mechanical artifact of deferred revenue unwinding, not evidence of fundamental strengthening. Investors should treat the reported current ratio and D/E with significant skepticism given this distortion.

TRDA — Frequently Asked Questions

Quick answers to the most common questions about buying TRDA stock.

What are the total assets of Entrada Therapeutics, Inc. (TRDA)?

As of 2025, Entrada Therapeutics, Inc. (TRDA) had total assets of $377.4M including $306.3M in current assets.

How much debt does Entrada Therapeutics, Inc. (TRDA) have?

Entrada Therapeutics, Inc. (TRDA) carries total debt of $50.9M, offset by $295.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Entrada Therapeutics, Inc.?

Entrada Therapeutics, Inc. (TRDA) has total shareholders' equity (book value) of $306.1M ($7.40 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Entrada Therapeutics, Inc.'s current ratio and liquidity?

Entrada Therapeutics, Inc. (TRDA) reported a current ratio of 12.53x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.